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Abstract
Background: Oral leukoplakia (OLK) is a potentially malignant disorder of the oral cavity. However, the underlying
mechanism of OLK is still unclear. In this study, we explore possible miRNAs involved in OLK.
Methodology/Principal Findings: Using miRNA microarrays, we profiled miRNA expression in OLK and malignantly
transformed OLK (mtOLK) tissue samples. The upregulation of miR-31*, miR-142-5p, miR-33a, miR-1259, miR-146b-5p, miR-
886-3p, miR-886-5p, miR-519d, and miR-301a along with the downregulation of miR-572, miR-611, miR-602, miR-675, miR-
585, miR-623, miR-637, and miR-1184 in mtOLK were new observations. Fluorescence in situ hybridization (FISH) analyses
confirmed that miR-31* is highly expressed in mtOLK. There was a significant difference between the FISH score (p,0.05) in
patients with or without recurrent/newly formed OLK. Functional analyses demonstrated that a miR-31* inhibitor decreased
apoptosis in the Leuk-1, which is an immortalized oral epithelial cell line spontaneously derived from an oral leukoplakia
lesion. miR-31* regulated apoptosis, cell proliferation, migration, and invasion in the HOIEC, which is a HPV E6/E7-
immortalized oral epithelial cell line. Furthermore, miR-31* modulated the biological functions of apoptosis, cell
proliferation, cell cycle, migration, and invasion in the oral squamous cell carcinoma cell line, Cal-27. Using bioinformatic
analyses and dual luciferase reporter assays, we determined that the 39 untranslated region of fibroblast growth factor 3
(FGF3) is the target of miR-31*. Expression of FGF3 was downregulated or upregulated in the presence of a miR-31* mimic
or inhibitor, respectively.
Conclusions/Significance: Upregulation of miR-31* is negatively associated with recurrent/newly formed OLK. MiR-31* may
exert similar but distinguishable effects on biological function in oral cells with different malignant potential. FGF3 is the
target of miR-31*. miR-31* may play an important role during OLK progression through regulating FGF3. MiRNA* strands
may also have prominent roles in oral carcinogenesis.
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Introduction
The development of oral squamous cell carcinoma (OSCC) is
considered a multistep process starting with hyperplasia, progress-
ing to dysplasia, and finally to neoplasm. During these steps,
multiple genetic alterations may occur, including chromosomal
aberrations as well as DNA mutations, amplification, or deletions
[1]. Therefore, oral leukoplakia (OLK) is recognized as an
excellent research model for oral carcinogenesis. OLK is a
potentially malignant disorder of the oral cavity, and presents as ‘‘a
predominantly white lesion of the oral mucosa that cannot be
characterized as any other definable disease’’ [2]. There are two
main clinical types of OLK, homogeneous and non-homogeneous,
that may affect any site of the oral cavity as a single, multiple, or
diffused lesion. Some OLKs resist treatment and exhibit local
recurrence (up to 30%) [3] or malignant transformation [4]. In
spite of tremendous progress in the field of molecular biology, the
underlying mechanism of OLK is still poorly understood.
MicroRNAs (miRNAs), a novel class of small non-coding RNAs
composed of 19–25 nucleotides, can post-transcriptionally regulate
gene expression by degrading mRNA or repressing translation [5].
More than one-quarter of all known human miRNAs are
significantly dysregulated in at least one cancer type, suggesting
that miRNAs may represent one of the largest classes of gene
regulators in cancer-related processes [6]. Several putative
oncogenic miRNAs have been identified in head and neck
squamous cell carcinoma, including miR-21, miR-184, and
miR-31 [7,8,9].
miRNA precursors, pre-miRNAs, are comprised of two strands:
the leading strand used for the production of mature miRNA and
the passenger strand (termed miRNA*) that is believed to be
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38648degraded [10]. However, recent studies have reported that many
miRNA* species are in fact relatively abundant and physically
associate with effector complexes [11,12,13]. However, there is
limited information about miRNAs* in relation to cancer.
In this study, we employed miRNA microarrays to identify
global changes of miRNA expression in OLK and malignantly
transformed OLK (mtOLK) tissue samples. We found 25
upregulated miRNAs and nine downregulated miRNAs with
greater than 2-fold changes in mtOLK. Fluorescence in situ
hybridization (FISH) was then used for further verification of one
of the significantly altered miRNAs, miR-31* and confirmed that
miR-31* was overexpressed in mtOLK. Functional analyses
indicate that miR-31* may exert similar but distinguishable effects
on biological function in oral cells with different malignant
potential. Furthermore, using bioinformatic analyses and dual
luciferase reporter assays, we demonstrated that the 39-untrans-
lated region (UTR) of fibroblast growth factor 3 (FGF3) is the
target of miR-31*. We also investigated changes in FGF3
expression in the presence of miR-31* mimics/inhibitors. Our
findings suggest miR-31* dysregulation is involved in the OLK
progression through regulating FGF3. miRNA* strands may also
have prominent roles in oral carcinogenesis.
Results
miRNA Expression Patterns Vary Significantly between
OLK and mtOLK
As compared with OLK tissue samples, there were 72
upregulated and 50 downregulated miRNAs found in mtOLK
(p,0.01). Unsupervised hierarchical clustering analyses of the 122
miRNAs revealed a marked separation of mtOLK and OLK,
suggesting this differential expression profile could be used as a
possible phenotypic discriminator between OLK and mtOLK
(Figure 1). Of the 122 altered miRNAs, 25 upregulated miRNAs
and nine downregulated miRNAs exhibited a greater than 2-fold
change in expression. As previously reported in other cancers
[14,15,16,17,18,19,20,21], we observed upregulation of miR-142-
3p, miR-223, miR-31, miR-21, let-7b*, miR-19a, miR-200a, miR-
200b, miR-30e, miR-146a, miR-141, miR-222, miR-374a, miR-
221, miR-24-2*, and miR-16 as well as downregulation of miR-
373*. However, the upregulation of miR-31*, miR-142-5p, miR-
33a, miR-1259, miR-146b-5p, miR-886-3p, miR-886-5p, miR-
519d, and miR-301a along with the downregulation of miR-572,
miR-611, miR-602, miR-675, miR-585, miR-623, miR-637, and
miR-1184 were new observations. Importantly, we noticed that
miR-31* and miR-31, which are derived from the same precursor,
are both upregulated in mtOLK.
Verification of miRNA Expression using FISH Analyses
Next, we performed FISH to verify and localize miR-31*
expression in 10 OLK and five mtOLK tissue samples. A positive
fluorescent miR-31* signal was found in 1/10 (10%) of OLK
patients and 4/5 (80%; p.0.05) of mtOLK patients. Interestingly,
one of the OLK tissue samples that was positive for miR-31* was
identified as severe dysplasia. Furthermore, the FISH score was
higher in mtOLK (mean=1.2) than in OLK (mean=0.2, p,0.05;
Table 1). In addition, no statistically significant differences were
found between a positive fluorescent miR-31* signal and gender,
age, epithelial dysplasia, or bad habits such as smoking and
excessive drinking and eating spicy/hot food and betel nut
chewing.
We also noticed that the unique OLK tissue sample expressing
miR-31* was negative for recurrent or newly formed OLK during
the follow-up. Meanwhile, the one mtOLK that had a FISH score
of 0 for miR-31* was found to have a newly formed OLK lesion
during the follow-up (Table 1). Therefore, we performed a
univariate regression model to analyze the relationship between
recurrent or newly formed OLK and such parameters as gender,
age, epithelial dysplasia, bad habits, malignant transformation,
and FISH scores. Only the FISH score (p,0.05) presented a
significant difference. In addition, miR-31* was mainly detected in
the inflammatory region, vascular area, and cancer nest of
mtOLK (Figure 2).
The Effect of miR-31* on the Biological Function of Oral
Cell Lines with Different Malignant Potential
Leuk-1 is an oral keratinocyte cell line with an immortalized but
non-tumorigenic phenotype. This cell line is spontaneously
derived from an oral leukoplakia lesion adjacent to OSCC [22].
After transfection with the miR-31* mimic, the number of
apoptotic cells increased by 30.5% (p,0.05). However, in the
presence of the miR-31* inhibitor, the percentage of apoptotic
Leuk-1 cells decreased by 11.2% (p.0.05). The migration and
invasion abilities of Leuk-1 cells transfected with the miR-31*
mimic decreased by 24.1% (p,0.05) and 33.8% (p,0.05), while in
the presence of the miR-31* inhibitor the migration and invasion
abilities increased by 80.45% (p,0.0001) and 3.38% (p.0.05),
respectively. miR-31* had only limited effects on cell proliferation
as well as cell cycle (Figure 3 and Figure S1).
HIOEC is an immortalized oral keratinocyte cell line induced
with HPV16 E6/E7 [23]. Subsequent treatment of HIOEC with
benzol[a]pyerene for 6 months resulted in the development of a
cancerous cell line [24]. The percentage of apoptotic cells was
slightly decreased (4.4%) in HIOEC cells in the presence of the
miR-31* inhibitor. Cell proliferation in the presence of the miR-
31* mimic was inhibited by 11.09% as compared with the negative
control. The migration and invasion abilities of HIOEC cells
transfected with the miR-31* inhibitor significantly increased by
154.2% (p,0.0001) and 12% (p,0.05). No significant effect of
miR-31* on cell cycle was found in HIOEC cells (Figure 3 and
Figure S2).
Proliferation of the OSCC cell line Cal-27 was inhibited 9.66%
(p.0.05) and the number of apoptotic cells increased 5.5%
(p,0.05) in the presence of the miR-31* mimic. The percentage of
Cal-27 cells in the S/G2 phase of the cell cycle increased by 7.6%
(p,0.05) upon transfection with the miR-31* inhibitor. The
migration and invasion abilities of Cal-27 cells transfected with the
miR-31* inhibitor significantly increased by 35% (p,0.05) and
21% (p,0.05), respectively (Figure 3 and Figure S3).
FGF3 is a Target of miR-31*
Four algorithms (PicTar, TargetScan, miRanda, and Micro-
Cosm Targets) were used to predict the putative targets of miR-
31*. Only MicroCosm Targets showed the candidate targets of
miR-31*, which included 655 genes (Table S1). Of these genes,
FGF3 and the interleukin 5 receptor a (IL5Ra) were selected for
further validation. We cloned the 39 UTR fragments of human
FGF3 or IL5Ra containing a wild type or mutant miR31*-binding
sequence into psiCHECKTM downstream of the luciferase
reporter gene. 293T cells transfected with psiCHECK-FGF3-
wild-type had a 64.79% decrease (p,0.0001) in relative luciferase
activity when cotransfected with the miR-31* mimic (Figure 4A).
The changes in relative luciferase activity observed upon
cotransfection of psiCHECK-FGF3-mutant with the miR-31*
mimic or negative control was not significant (p.0.05). These
findings suggest a direct interaction between miR-31* and the 39
UTR of FGF3. On the other hand, changes in IL5Ra as measured
by dual luciferase reporter assay were limited (Figure 4B).
miR-31* in Oral Leukoplakia
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38648Figure 1. Unsupervised hierarchical cluster analysis of miRNA expression in OLK and mtOLK. The marked separation of OLK and mtOLK
based on the miRNAs profiling is exhibited. Scale is shown in the upper right. Red represents a high expression and green represents a low
expression. OLK, oral leukoplakia; mtOLK, malignant transformed oral leukoplakia.
doi:10.1371/journal.pone.0038648.g001
Figure 2. FISH detection of miR-31* expression in OLK and mtOLK. (A) , (C), no positive signal is detected in OLK. (D) , (L), the
representative positive signals are showed in mtOLK. (D) , (F), tumor nest; (G) , (I), vascular area; (J) , (L), inflammation. FISH signals are visualized
in green, while blue depicts nuclear DAPI stain. OLK, oral leukoplakia; mtOLK, malignant transformed oral leukoplakia.
doi:10.1371/journal.pone.0038648.g002
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polymerase chain reaction (QRT-PCR) to examine the mRNA
expression of FGF3 in the presence of miR-31* mimics/inhibitors.
The decreased/increased mRNA expression of FGF3 was found
when transfected with miR-31* mimics/inhibitors in Leuk-1,
HIOEC and Cal-27 (Figure 5A). Western blot analyses showed
that miR-31* mimics/inhibitors significantly attenuated/increased
the FGF3 protein expressions in all three oral cell lines (Figure 5B).
Together, these data suggest that FGF3 is a target gene of miR-31*
and FGF3 expression is altered during OLK progression.
Discussion
OLK is the most common premalignant lesion of the oral
mucosa. To our knowledge, this is the first study that identifies
alterations in miRNA expression between OLK and mtOLK. We
found 25 upregulated miRNAs and nine downregulated miRNAs
with greater than 2-fold changes in mtOLK. The miRNA profile
identified was significantly different between OLK and mtOLK,
providing evidence that miRNAs may serve as potential biomark-
ers in the process of OLK malignant transformation.
Among these altered miRNAs, miR-31* was chosen for further
study for three reasons. First, miR-31* showed a significant fold
change among the upregulated miRNAs. Also, this is the first
report of altered miR-31* expression in cancer. Finally, miR-31* is
derived from the same precursor with miR-31 and miR-31 was
also overexpressed in the mtOLK samples studied. MiRNA*, the
passenger strand of miRNA, is believed to be eliminated by
cleavage or a bypass mechanism based on the ‘strand bias’ theory
[10,25]. However, recent studies have reported that many
miRNA* species are actually relatively abundant and physically
associated with effector complexes [11,12,13]. There is limited
knowledge about miRNA*, especially its relationship to carcino-
genesis. Therefore, our analyses of miR-31* in OLK and mtOLK
elucidates the role of miRNA in OLK malignant transformation
but also demonstrates the potential role of miRNA* in carcino-
genesis.
Since a combination of different methods makes results more
reliable [26], FISH was performed in the present study. These
data consistently demonstrated miR-31* upregulation in mtOLK,
but also allowed for visualization of the miR-31* signal. Therefore,
FISH is a useful method to localize miRNA expression in frozen
tissue sections [27].
In our study, all patients with a high FISH score, which
included one OLK patient and three mtOLK patients, did not
have recurrent or newly formed OLK during follow-up studies. In
functional analysis, miR-31* greatly modulated the ability of
apoptosis and migration in Leuk-1, HIOEC, and Cal-27 cells.
However, in Cal-27 cells, miR-31* also modulated cell prolifer-
ation and cell cycle. Given these data, high miR-31* expression
enhanced apoptosis and migration of potentially malignant cells as
well as oral cancerous cells. The ability of miR-31* to modulate
apoptosis and migration may be sufficient to prevent OLK
recurrence or new leukoplakia growth.
MiR-31 has oncogenic functions in head and neck squamous
cell carcinoma [9,28]. Functional analyses of miR-31* may also
broaden our understanding of miRNA* strands, especially those
that are simultaneously expressed and paired miRNAs. Our results
suggest that in addition to miR-31, miR-31* also has a biological
function in cancer development.
Since establishing the multistep process of oral carcinogenesis,
various oral keratinocyte cell lines have been used in the oral
cellular model [22,23]. Leuk-1 is spontaneously derived from an
oral leukoplakia lesion that was adjacent to OSCC. It exhibits an
immortalized but non-tumorigenic phenotype [22]. HIOEC is
HPV16 E6/E7 immortalized oral keratinocyte cell line [23]. By
induction with benzol[a]pyerene for 6 months, HIOEC cells
become the cancerous cell line, HIOEC-BaP-96 (HB96) [24]. In
our study, we used Leuk-1 and HIOEC cells, representing the
precancerous stage in the cellular model. Indeed, miR-31*
significantly modulated apoptosis and migration in Leuk-1 and
HIOEC cells. In HIOEC cells, but in not Leuk-1 cells, miR-31*
also affected cell proliferation. It suggests that miR-31* has similar
but distinguishable effects in oral cell lines. The different effects in
the various in vitro systems may be due to differences between
organ systems and methods of immortalization (e.g., viral versus
spontaneous) [22]. We used an oral cancer cell line, Cal-27, to
represent the final stage in the cellular model of oral carcinogen-
esis. miR-31* modulated a variety of biological functions in Cal-27
cells, including cell proliferation, cell cycle, apoptosis, migration,
and invasion. Taken together, miR-31* acted as a tumor
suppressor associated gene in oral carcinogenesis. However,
miR-31* may have different effects on biological function in oral
cells with different malignant potential. Therefore, one should be
cautious when addressing the roles of miR-31* in OLK malignant
transformation. Given the notion that miR-31* is located in the
cancer nest of mtOLK, further studies are needed to investigate
whether the function of miR-31* is antagonistic to miR-31.
At present, the lack of knowledge regarding miRNA-targeted
genes has hampered full understanding of cancer pathways that
may be dysregulated by aberrant miRNA expression. To
overcome this limitation, we used currently available computa-
tional approaches to predict gene targets. We found 655 candidate
targets of miR-31* using the MicroCosm Targets program. These
genes were involved in cytokine-cytokine receptor interactions,
Chagas disease, the Jak-STAT signaling pathway, calcium
signaling pathways, carbohydrate digestion and absorption,
hematopoietic cell lineage determination, regulation of the actin
cytoskeleton, and toxoplasmosis. We detected miR-31* expression
Table 1. Clinical outcomes in OLK and mtOLK.
ID Lesion
Epithelial
dysplasia
FISH
score Recurrent
Newly
formed
Follow-
up
(months)
1 OLK ND 0 NA NA 27
2 OLK MiD 0 (+)( 2)4 7
3 OLK MiD 0 NA NA 29
4 OLK MiD 0 (+)( 2)2 0
5 OLK MoD 0 (+)( 2)3 7
6 OLK MoD 0. (2)( 2)3 0
7 OLK SD 0 (+)( 2)4 2
8 OLK SD 0 NA NA 32
9 OLK SD 0 (2)( 2)2 9
10 OLK SD 2 (2)( 2)3 0
11 mtOLK SCC 0 (2)( +)3 6
12 mtOLK SCC 2 (2)( 2)2 8
13 mtOLK SCC 1 (2)( 2)3 3
14 mtOLK SCC 1 NA NA 21
15 mtOLK SCC 2 (2)( 2)2 1
OLK, oral leukoplakia; mtOLK, malignant transformed oral leukoplakia; ND, no
dysplasia; MiD, mild dysplasia; MoD, moderate dysplasia; SD, severe dysplasia;
SCC, squamous cell carcinoma; NA, not available.
doi:10.1371/journal.pone.0038648.t001
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supports the hypothesis that miR-31* regulates genes related to
cytokine-cytokine receptor interactions, Jak-STAT signaling, or
hematopoietic cell lineage determination.
FGF3 was identified by its similarity with mouse fgf3/int-2, a
proto-oncogene activated in virally induced mammary tumors in
the mouse [29]. The protein encoded by this gene is a member of
fibroblast growth factor family and plays a role in various processes
such as cell proliferation, angiogenesis, and embryogenesis [30]. In
normal human breast tissue, expression of this gene is undetectable
and it is expressed at low levels in the healthy brain and testis [31].
Ectopic expression of FGF3 in prostate epithelial cells elicits rapid
hyperplasia [32]. In the FGF3 stably transfected mouse epithelial
cell line, FSK4, expression of FGF3 causes proliferative changes,
including reduced contact inhibition, increased b-catenin expres-
sion, and decreased p53 transcriptional activity [33]. Hajitou et al.
found that FGF3-transfected EF43 mouse cells were strongly
invasive in matrigel-coated chambers and caused tumor metasta-
ses in nude mice [34]. Hu et al. used a hepatocellular carcinoma
tissue microarray and found that FGF3 overexpression is
significantly associated with hepatocellular carcinoma metastasis
and recurrence, suggesting that FGF3 upregulation may play an
important role in these processes [35]. Studies have also shown
amplification of FGF3 in nasopharyngeal carcinoma [36], ovarian
cancer [37], endometrial carcinomas [38], lung cancer [39], and
oral cancer [40,41,42,43], which may be important for neoplastic
transformation and tumor progression. Here, we first provide
evidence that the 39 UTR of FGF3 physically combines with miR-
31*. We also showed that miR-31* could negatively regulate FGF3
expression level in oral cells. It suggests that miR-31* may play a
role through regulating FGF3 during OLK progression. We
noticed that FGF3 expression was decreased but not completely
ablated when over-expressing miR-31* in Cal-27. This data
indicates that regulating of FGF3 expression may involve multiple
factors and miR-31* is one of the effecter to down regulate FGF3.
Taken together, upregulation of miR-31* is negatively corre-
lated with recurrent/newly formed OLK. MiR-31* may exert
different effects on biological function in oral cells with different
malignant potential. FGF3 is the target of miR-31* and miR-31*
may play an important role during OLK progression through
regulating FGF3. Our data further suggest that miRNA* strands
may also have prominent roles in oral carcinogenesis.
Materials and Methods
Patients and Samples
Twenty-seven tissue samples (20 OLK and seven mtOLK) were
collected from patients of the Department of Oral Mucosal
Diseases and the Department of Oral and Maxillofacial Surgery,
Ninth People’s Hospital, Shanghai Jiao Tong University School of
Medicine. The diagnosis of OLK, mtOLK, and epithelial
dysplasia were made according to World Health Organization
criteria [27]. Tumor-node-metastasis classification [44] was also
applied to mtOLK patients. Baseline characteristics of the patients
are shown in Table 2. To identify changes in miRNA expression
between OLK and early-stage mtOLK, all mtOLK patients
enrolled in the study were classified as T1N0M0. The mean follow-
Figure 3. Representative results of miR-31* effects on biological functions. (A) the MTT assay in HIOEC; (B) the Annexin V assay in Leuk-1;
(C) flow cytometry analysis for cell cycle in Cal-27; (D) representative field of view of HIOEC invasion inserts at a 1006magnification, (Da) miR-31*
mimic, (Db) miR-31* inhibitor, (Dc) negative control, (Dd) Quantification of relative numbers of invading cells representing average counts from 6
fields-of-view per insert per sample 6SD, **p,0.05, ***p,0.001; (E) representative field of view of HIOEC migration inserts at a 1006magnification,
(Ea) miR-31* mimic, (Eb) miR-31* inhibitor, (Ec) negative control, (Ed) quantification of relative numbers of invading cells representing average counts
from 6 fields-of-view per insert per sample 6SD, **p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0038648.g003
Figure 4. Dual luciferase reporter assay for miR-31* and targeted genes. (A) Psicheck-FGF3-wt/mt and miR-31*; (B) Psicheck-IL5Ra-wt/mt
and miR-31*. NC = negative control; mimic = miR-31* mimic; wt = wild type; mt = mutant type.
doi:10.1371/journal.pone.0038648.g004
miR-31* in Oral Leukoplakia
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were diagnosed as squamous cell carcinoma upon collection, with
a history of OLK at the same site. This study was approved by the
Human Research Ethics Committee of Shanghai Ninth People’s
Hospital, Shanghai Jiao Tong University School of Medicine
(#200703). Informed written consent was obtained from all
patients before sampling.
RNA Isolation and miRNA Microarray
Total RNA was isolated from all samples using TRIZOL
reagent (Invitrogen, USA) according to the manufacturer’s
protocol. We employed miRCURY
TM Locked Nucleic Acid
Array version 11.0 (Exiqon, Denmark), which contains capture
probes for all human miRNAs (847 total), to identify the miRNA
expression profile in OLK tissues, as previously described [45].
Scanning was performed using the Axon GenePix 4000B
microarray scanner (Axon Instruments, USA). GenePix Pro 6
was used to read the raw intensity of the image. The ratio of red
signals to green signals was calculated after background subtrac-
tion and normalization using the global Lowess regression
algorithm. Significant miRNAs were selected and unsupervised
hierarchical clustering was also performed on the miRNA
expression profile. All data is Minimum Information About a
Microarray Experiment-compliant and the raw data has been
deposited in a Minimum Information About a Microarray
Experiment-compliant database (GEO), as detailed on the
Microarray Gene Expression Data Society website. The accession
number is GSE33299 and the website address is www.ncbi.nlm.
nih.gov/geo.
FISH Detection
FISH was performed as previously described, with some
modifications [46]. In brief, 10– mm frozen tissue sections were
fixed and pre-hybridized at 51uC. Locked nucleic acid-modified
and fluorescein isothiocyanate-labeled oligonucleotide probes
(3 pmol; Exiqon) were hybridized to the sections at 51uC. The
sections were incubated with a fluorescein isothiocyanate/horse-
radish peroxidase primary antibody (DAKO, Denmark). Signals
were detected using the tyramide signal amplification system
(Perkin-Elmer, USA) and analyzed with Image-Pro Plus software.
The FISH score was based on both the intensity of staining and
percentage of positive cells. The scale for staining intensity was 0
(negative), 1 (weak), or 2 (strong). The percentage of positive cells
was defined as 0 (0%), 1 (interspersed or 0–10%), 2 (focal or 10–
50%), or 3 (diffuse or .50%). A ‘‘FISH score’’ was generated as
the product of intensity times area, similar to what has been
previously described [47].
Cell Culture and Transfection
The human oral leukoplakia cell line Leuk-1 was kindly
provided by Dr. Li Mao (MD Anderson Cancer Center, USA).
It is spontaneously derived from an oral leukoplakia lesion that was
Figure 5. miR-31* mimics/inhibitors regulating mRNA and protein expression of FGF3 in oral cells. (A) QRT-PCR analysis of FGF3
expression in Leuk-1, HIOEC and Cal-27 cell lines, **p,0.05; (B) Western blot analysis of of FGF3 expression in Leuk-1, HIOEC and Cal-27 cell lines
transfected with miR-31* mimic, miR-31* inhibitor and negative control. The representative blot is shown (upper for FGF3). The histogram shows the
average volume density normalized by the loading control, GAPDH (lower).
doi:10.1371/journal.pone.0038648.g005
Table 2. Baseline characteristics of the subjects studied.
OLK (20) mtOLK (7) P
Gender 0.678
Male 11 3
Female 9 4
Age (years) mean 6 SD 59.0069.33 55.43616.33 0.564
Smoking 1.000
Never/Former 11 4
Current 9 3
Alcohol consumption 1.000
Never/Former 8 3
Current user 12 4
Epithelial dysplasia
None/Mild 11 – –
Moderate 5 – –
Severe 4 – –
TNM classification
T1N0M0 –7 –
OLK, oral leukoplakia; mtOLK, malignant transformed oral leukoplakia; SD,
standard deviation; TNM, tumor-node-metastasis.
doi:10.1371/journal.pone.0038648.t002
miR-31* in Oral Leukoplakia
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tumorigenic phenotype [7]. The human immortalized oral
epithelial cell line, HIOEC, was established by the Shanghai
Key Laboratory of Stomatology, which was obtained from normal
oral mucosa immortalized with HPV16 E6/E7 gene transfection.
Both of these cell lines were cultured in keratinocyte media-serum-
free media (Gibco, USA). The oral cancer cell line Cal-27
(American Type Culture Collection, USA) was grown in
Dulbecco’s modified Eagle medium (Gibco). The miR-31* mimic
(C-301029-01-0005), inhibitor (IH-301029-02-0005), and negative
control (IN-001005-01-05) were all purchased from Thermo
Scientific Dharmacon (USA). Cells were transfected 24 h after
plating using Lipofectamine 2000 reagent (Invitrogen). Transfec-
tion complexes were prepared according to the manufacturer’s
instructions.
MTT Assays
Cells were seeded in 96-well plates at a density of 5000 cells/
well. At various time points post-transfection (24 h, 48 h, and
72 h), 20 ml of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo-
lium bromide (MTT) was added to the test well and incubated for
4 h. The supernatant was then discarded and 200 ml of dimethyl
sulfoxide was added. Absorbance was measured at a wavelength of
490 nm using a microplate reader (Tecan Sunrise, Austria). Each
experiment was repeated in triplicate.
Cell Cycle Analyses
Parental and transfected cells in the log phase of growth were
stained with propidium iodide [48] and examined using a
FACScan flow cytometer (BD Biosciences, USA). DNA histograms
were analyzed with ModFit LT for Mac V 3.1 (Verity Software
House, USA).
Annexin V Assays
Apoptosis was measured using an Annexin V/7-AAD flow
cytometric assay (BD Biosciences) according to the manufacturer’s
instructions and then analyzed using a FACScan flow cytometer.
Data analyses were performed using Cell-Quest software (BD
Biosciences). All experiments were run in triplicate.
Cell Migration and Invasion Assays
After transfection, cells were incubated for 12 h in serum-free
media. Transwell inserts with 8– mm pores were purchased from
Millipore Corporation (USA). Cells (20610
5) were resuspended in
the upper chamber in 200 ml serum-free media and incubated for
16 h for the migration assay. For the invasion assay, 8.0610
5 cells
in 200 ml serum-free media were added to the matrigel-coated
upper chamber and incubated for 48 h. Cells on the lower surface
of the insert were Giemsa (Cal-27 and Leuk-1) or Coomassie
brilliant blue (HIOEC) stained and images from five representative
fields of each membrane were taken using a light microscope
(1006magnification). The number of migratory or invasive cells
was counted. Each experiment was repeated three times.
Bioinformatics
The following online software programs were used to seek
candidate targets of miR-31*: PicTar (http://pictar.bio.nyu.edu),
TargetScan 4.1 (http://www.targetscan.org), MicroCosm Targets
Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm/cgi-
bin/targets/v5/search.pl), and miRanda (http://cbio.mskcc.org/
cgi-bin/mirnaviewer/mirnaviewer.pl). The MicroCosm Targets
software program was the only one to show candidate targets of
miRNA-31*. GeneCodis 2.0 [49,50] was then used to search for
biological features and pathway enrichment analyses of the
interacting genes involved in the network.
Plasmid Construction
To evaluate the binding of miR-31* to FGF3, its 39UTR (NM-
005247) was amplified by PCR using the primers 59-GCCTCGA-
GACCTGGAGCCCTCTCACGTT-39 and 59-
CAGCGGCCGCGCTGTGCTGGAAGCAAGCAC-39. The
product was cloned into XhoI and NotI sites of the psi-
CHECKTM-2 vector (Promega, USA) for subsequent luciferase
assays. Mutations on the complementary site were introduced by
PCR mutagenesis using the QuikChange site-directed mutagenesis
kit protocol (Stratagene, USA) and were confirmed by DNA
sequencing. The 39 UTR (NM-000564) of IL5Ra was also
amplified by PCR using the primers 59-GCCTCGAGGCCTG-
GAGTTGAGACCCTGG-39 and 59-
CAGCGGCCGCGGGGGTGAGGAATTTGTGGCT-39. The
product was then cloned into psiCHECKTM-2 as described
above.
Dual Luciferase Reporter Assays
293T cells were seeded at a density of 2.5610
4 cells/well in a
12-well plate and grown for 48 h. A total of 400 ng of the plasmids
(psiCHECK-FGF3-wild type/psiCHECK -IL5Ra -wild type and
psiCHECK-FGF3-mutant/psiCHECK -IL5Ra -mutant) were
cotransfected with 50 pmol miR-31* using Lipofectamine 2000
(Invitrogen). After 24 h, cell extracts were obtained and firefly and
renilla luciferase activities were measured with the dual-luciferase
reporter system (Promega) according to the manufacturer’s
instructions.
QRT-PCR
A two-step QRT-PCR was performed using SuperScriptH
Reverse Transcription Kits (Invitrogen, USA) and SYBRH Green
Master Mixes (Invitrogen, USA) according to the manufacturer’s
instructions. In brief, the total RNA of every sample was converted
into cDNA using random primer. Then quantitative PCR was
performed in a Step-One Plus Real-Time PCR System (Applied
Biosystems, USA). The reaction conditions were applied according
to the manufacturer’s manually, which were 95uC for 2 min,
followed by 40 cycles of 94uC for 10 sec and 58uC for 10 sec and
72uC for 40 sec. All samples were completed in triplicate. The
GAPDH was used as internal control and the relative expression
level of FGF3 was determined using comparative CT method (2
-
DDCT). The following primers were used: for FGF3, 59-
GTACCACCTCCAGCTGCACC -39 (forward) and 59-
GCGTACTAGACACCGTCCGG -39 (reverse); and for
GAPDH, 59- AATTCCATGGCACCGTCAAG -39 (forward)
and 59- TGGTTCACACCCATGACGAA -39 (reverse).
Western Blotting
Cell extracts were prepared in lysis buffer and centrifuged at
12,0006g at 4uC. The total protein concentration was measured
using a bicinchoninic acid assay. Cellular extracts containing
50 mg total protein were analyzed using 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred electro-
phoretically to polyvinylidene difluoride membranes (Invitrogen,
USA). Blots were probed at 4uC overnight with primary antibodies
in 5% milk/TBST. The antibodies used for western blotting were
FGF3 and GAPDH (Abcam Ltd., UK).
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Student’s t-tests for two groups or one-way analysis of variance
were performed to evaluate the statistical significance of clustered
miRNAs in each group as well as in the functional assays. The x
2
test was used to analyze the difference in the rate of FISH between
OLK and mtOLK. Fisher’s exact tests and logistic regression
models were used to analyze the relationship between clinical
parameters and miRNA. Data analyses were performed using
SPSS for Windows version 16.0 (SPSS Inc., USA). Tests were two-
sided and p,0.05 was considered statistically significant.
Supporting Information
Figure S1 Effects on biological functions of miR-31* in
Leuk-1. (A) the MTT assay in Leuk-1; (B) the Annexin V assay in
Leuk-1; (C) flow cytometry analysis for cell cycle in Leuk-1; (D)
representative field of view of Leuk-1 invasion inserts at a 1006
magnification, (Da) miR-31* mimic, (Db) miR-31* inhibitor, (Dc)
negative control, (Dd) Quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001; (E) represen-
tative field of view of Leuk-1 migration inserts at a 1006
magnification, (Ea) miR-31* mimic, (Eb) miR-31* inhibitor, (Ec)
negative control, (Ed) quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001.
(TIF)
Figure S2 Effects on biological functions of miR-31* in
HIOEC. (A) the MTT assay in HIOEC; (B) the Annexin V assay
in HIOEC; (C) flow cytometry analysis for cell cycle in HIOEC;
(D) representative field of view of HIOEC invasion inserts at a
1006magnification, (Da) miR-31* mimic, (Db) miR-31* inhibitor,
(Dc) negative control, (Dd) Quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001; (E) represen-
tative field of view of HIOEC migration inserts at a 1006
magnification, (Ea) miR-31* mimic, (Eb) miR-31* inhibitor, (Ec)
negative control, (Ed) quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001.
(TIF)
Figure S3 Effects on biological functions of miR-31* in
Cal-27. (A) the MTT assay in Cal-27; (B) the Annexin V assay in
Cal-27; (C) flow cytometry analysis for cell cycle in Cal-27; (D)
representative field of view of Cal-27 invasion inserts at a 1006
magnification, (Da) miR-31* mimic, (Db) miR-31* inhibitor, (Dc)
negative control, (Dd) Quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001; (E) represen-
tative field of view of Cal-27 migration inserts at a 1006
magnification, (Ea) miR-31* mimic, (Eb) miR-31* inhibitor, (Ec)
negative control, (Ed) quantification of relative numbers of
invading cells representing average counts from 6 fields-of-view
per insert per sample 6SD, **p,0.05, ***p,0.001.
(TIF)
Table S1 The related pathways of the targeted genes of
miR-31*.
(DOC)
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